Barclays analyst Andrew Mok lowered the firm’s price target on CVS Health (CVS) to $71 from $75 and keeps an Overweight rating on the shares post the Q3 report. Despite the setback, CVS looks poised to recover margin under new Aetna President Steve Nelson, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health’s (CVS) New CEO Announces Leadership Changes amid Challenges at Aetna
- CVS Health Corp Reports Q3 2024 Earnings
- Trump Media, broader market surge after Trump wins election: Morning Buzz
- CVS Earnings: CVS Health Surges Despite Mixed Q3 Results; No Formal Outlook
- Unusually active option classes on open November 6th